Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain

Journal of Molecular Biology

Volumn 399, Issue 3, 2010, Pages 347-357

  Leung, Daisy W ^a   Shabman, Reed S ^b   Farahbakhsh, Mina ^a   Prins, Kathleen C ^b   Borek, Dominika M ^c   Wang, Tianjiao ^a   Mühlberger, Elke ^d,e   Basler, Christopher F ^b   Amarasinghe, Gaya K ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e National Emerging Infectious Diseases Laboratories Institute   (United States)

Author keywords

Ebola VP35; Immune evasion; Viral protein structure

Indexed keywords

DOUBLE STRANDED RNA; EVOLA VIRUS VP35 PROTEIN; INTERFERON; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BIOCHEMISTRY; CRYSTAL STRUCTURE; EBOLA VIRUS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MUTATION; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; RESTON EBOLA VIRUS; VIROLOGY;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; PRIMATES; RESTON EBOLAVIRUS; ZAIRE EBOLAVIRUS;

EID: 77954757071     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.04.022     Document Type: Article

References (58)

1. Bray M., Geisbert T.W. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int. J. Biochem. Cell Biol. 2005, 37:1560-1566.
2. Bray M., Murphy F.A. Filovirus research: knowledge expands to meet a growing threat. J. Infect. Dis. 2007, 196:S438-S443.
3. Feldmann H., Klenk H.D. Marburg and Ebola viruses. Adv. Virus Res. 1996, 47:1-52.
4. Geisbert T.W., Hensley L.E. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert. Rev. Mol. Med. 2004, 6:1-24.
5. Barrette R.W., Metwally S.A., Rowland J.M., Xu L., Zaki S.R., Nichol S.T., et al. Discovery of swine as a host for the Reston Ebolavirus. Science 2009, 325:204-206.
6. Ebola Reston virus detected pigs in the Philippines. Euro Surveill. 2009, 14. Editorial Team, pii=19105.
7. Outbreak news. Ebola Reston in pigs and humans, Philippines. Wkly. Epidemiol. Rec. 2009, 84:49-50.
8. Kash J.C., Muhlberger E., Carter V., Grosch M., Perwitasari O., Proll S.C., et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 2006, 80:3009-3020.
9. Boehmann Y., Enterlein S., Randolf A., Muhlberger E. A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology 2005, 332:406-417.
10. Noda T., Halfmann P., Sagara H., Kawaoka Y. Regions in Ebola virus VP24 that are important for nucleocapsid formation. J. Infect. Dis. 2007, 196:S247-S250.
11. Reid S.P., Leung L.W., Hartman A.L., Martinez O., Shaw M.L., Carbonnelle C., et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 2006, 80:5156-5167.
12. Reid S.P., Valmas C., Martinez O., Sanchez F.M., Basler C.F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 2007, 81:13469-13477.
13. Feng Z., Cerveny M., Yan Z., He B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 2007, 81:182-192.
14. Schumann M., Gantke T., Muhlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 2009, 83:8993-8997.
15. Cardenas W.B., Loo Y.M., Gale M., Hartman A.L., Kimberlin C.R., Martinez-Sobrido L., et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 2006, 80:5168-5178.
16. Hartman A.L., Dover J.E., Towner J.S., Nichol S.T. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 2006, 80:6430-6440.
17. Haasnoot J., de Vries W., Geutjes E.J., Prins M., de Haan P., Berkhout B. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 2007, 3:e86.
18. Leung D.W., Ginder N.D., Fulton D.B., Nix J., Basler C.F., Honzatko R.B., Amarasinghe G.K. Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl Acad. Sci. USA 2009, 106:411-416.
19. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
20. Cummings M.D., Farnum M.A., Nelen M.I. Universal screening methods and applications of ThermoFluor. J. Biomol. Screen. 2006, 11:854-863.
21. Ericsson U.B., Hallberg B.M., Detitta G.T., Dekker N., Nordlund P. ThermoFluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 2006, 357:289-298.
22. Moller P., Pariente N., Klenk H.D., Becker S. Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription. J. Virol. 2005, 79:14876-14886.
23. Reid S.P., Cardenas W.B., Basler C.F. Homo-oligomerization facilitates the interferon-antagonist activity of the Ebolavirus VP35 protein. Virology 2005, 341:179-189.
24. Basler C.F., Mikulasova A., Martinez-Sobrido L., Paragas J., Muhlberger E., Bray M., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77:7945-7956.
25. Hartman A.L., Towner J.S., Nichol S.T. A C-terminal basic amino acid motif of Zaire Ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004, 328:177-184.
26. Leung D.W., Prins K.C., Borek D.M., Farahbakhsh M., Tufariello J.M., Ramanan P., et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 2010, 17:165-172.
27. Huang Y., Xu L., Sun Y., Nabel G.J. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol. Cell 2002, 10:307-316.
28. Shi W., Huang Y., Sutton-Smith M., Tissot B., Panico M., Morris H.R., et al. A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J. Virol. 2008, 82:6190-6199.
29. Johnson R.F., Bell P., Harty R.N. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol. J. 2006, 3:31.
30. Noda T., Sagara H., Suzuki E., Takada A., Kida H., Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 2002, 76:4855-4865.
31. Hartman A.L., Ling L., Nichol S.T., Hibberd M.L. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J. Virol. 2008, 82:5348-5358.
32. Prins K.C., Cardenas W.B., Basler C.F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 2009, 83:3069-3077.
33. Prins K.C., Delpeut S., Leung D.W., Reynard O., Volchkova V.A., Reid S.P., et al. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 2010, 84:3004-3015.
34. Hartman A.L., Bird B.H., Towner J.S., Antoniadou Z.A., Zaki S.R., Nichol S.T. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of Ebola virus. J. Virol. 2008, 82:2699-2704.
35. Morikawa S., Saijo M., Kurane I. Connaissances actuelles sur la moindre virulence du virus Ebola Reston (Current knowledge on lower virulence of Reston Ebola virus) in French. Comp. Immunol. Microbiol. Infect. Dis. 2007, 30:391-398.
36. Leung D.W., Ginder N.D., Nix J.C., Basler C.F., Honzatko R.B., Amarasinghe G.K. Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain. Acta Crystallogr. Sect. F 2009, 65:163-165.
37. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
38. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D 1994, 50:760-763. Collaborative Computational Project.
39. Vagin A.A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022.
40. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. Sect. D 2001, 57:1373-1382.
41. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D 1997, 53:240-255.
42. Lamzin V.S., Wilson K.S. Automated refinement of protein models. Acta Crystallogr. Sect. D 1993, 49:129-147.
43. Perrakis A., Sixma T.K., Wilson K.S., Lamzin V.S. wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models. Acta Crystallogr. Sect. D 1997, 53:448-455.
44. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 2004, 60:2126-2132.
45. Painter J., Merritt E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. Sect. D 2006, 62:439-450.
46. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
47. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA, USA.
48. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6:277-293.
49. Johnson B.A. Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol. Biol. 2004, 278:313-352.
50. Fujita T., Onoguchi K., Onomoto K., Hirai R., Yoneyama M. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie 2007, 89:754-760.
51. Matsukura S., Kokubu F., Kurokawa M., Kawaguchi M., Ieki K., Kuga H., et al. Role of RIG-I, MDA-5, and PKR on the expression of inflammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int. Arch. Allergy Immunol. 2007, 143:80-83.
52. Takeuchi O., Akira S. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 2008, 20:17-22.
53. Yoneyama M., Fujita T. RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity. Cytokine Growth Factor Rev. 2007, 18:545-551.
54. Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 2005, 175:2851-2858.
55. Hausmann S., Marq J.B., Tapparel C., Kolakofsky D., Garcin D. RIG-I and dsRNA-induced IFNbeta activation. PLoS ONE 2008, 3:e3965.
56. Saito T., Gale M. Principles of intracellular viral recognition. Curr. Opin. Immunol. 2007, 19:17-23.
57. Spiropoulou C.F., Ranjan P., Pearce M.B., Sealy T.K., Albarino C.G., Gangappa S., et al. RIG-I activation inhibits Ebolavirus replication. Virology 2009, 392:11-15.
58. Kimberlin C.R., Bornhold Z.A., Li S., Woods V.L., MacRae I.J., Saphire E.O. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc. Natl Acad. Sci. USA 2010, 107:314-319.